Ameliorative role of camel whey protein and rosuvastatin on induced dyslipidemia in mice,Food & Function

当前位置： X-MOL 学术 › Food Funct. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Ameliorative role of camel whey protein and rosuvastatin on induced dyslipidemia in mice
Food & Function ( IF 5.1 ) Pub Date : 2018-01-02 00:00:00 , DOI: 10.1039/c7fo01871a
Nashwa Ahmed El-Shinnawy _{1,

2,

3,

4,

5} , Sahar Sobhy Abd Elhalem _{1,

2,

3,

4,

5} , Nawal Zakaria Haggag _{1,

2,

3,

4,

5} , Gamal Badr _{1,

6,

7,

8,

9}

Affiliation

The incidence of obesity is rapidly increasing throughout the world. Dyslipidemia is a major risk factor for a number of chronic diseases, including diabetes and cardiovascular diseases. This work presents a novel approach to study the activity of camel whey protein (WP) with antioxidant and anti-inflammatory properties as a cheap dietary protein substance extracted from camel milk to produce satiety and help in building muscles. Mice model suffering from dyslipidemia as a result of feeding on high fat-cholesterol diet for 8 weeks were administrated with either camel WP and/or rosuvastatin for 4 weeks. Dyslipidemia revealed significant increase in anthropometrical measurements, levels of glucose, insulin, cholesterol, triglycerides, low-density lipoprotein, total leucocyte count, inflammatory cytokines and reactive oxygen species, accompanied by a significant elevation in activating transcription factor-3 and inducible nitric oxide synthase expressions. These alterations were correlated with a profound reduction in high-density lipoprotein, peroxisome proliferator-activated receptor alpha and adiponectin along with a decrease in liver and muscle mitochondrial proteins. Rosuvastatin treatment to mice suffering from dyslipidemia in combination with camel WP for 4 weeks ameliorated these parameters. Notably, animals treated with both camel WP and rosuvastatin exhibited a remarkable decrease in the incidence of dyslipidemia. In addition, camel WP succeeded to overcome the therapeutic drawback posed from rosuvastatin therapy alone with minimal side effects.

中文翻译：

骆驼乳清蛋白和瑞舒伐他汀对小鼠血脂异常的改善作用

肥胖的发生率在世界范围内迅速增加。血脂异常是许多慢性疾病的主要危险因素，包括糖尿病和心血管疾病。这项工作提出了一种新颖的方法来研究具有抗氧化和抗炎特性的骆驼乳清蛋白（WP）的活性，骆驼乳清蛋白是一种从骆驼奶中提取的廉价饮食蛋白物质，可产生饱腹感并有助于增强肌肉。饲喂高脂胆固醇饮食8周而导致血脂异常的小鼠模型与骆驼可湿性粉剂和/或瑞舒伐他汀一起给药4周。血脂异常表明人体测量值，葡萄糖，胰岛素，胆固醇，甘油三酸酯，低密度脂蛋白，白细胞总数，炎性细胞因子和活性氧的含量显着增加，伴随着激活转录因子3和诱导型一氧化氮合酶表达的显着提高。这些改变与高密度脂蛋白，过氧化物酶体增殖物激活的受体α和脂联素的大量减少以及肝脏和肌肉线粒体蛋白质的减少有关。瑞舒伐他汀对血脂异常的小鼠与骆驼WP联合治疗4周可改善这些参数。值得注意的是，骆驼可湿性粉剂和瑞舒伐他汀同时治疗的动物血脂异常的发生率显着降低。此外，骆驼可湿性粉剂成功克服了仅由瑞舒伐他汀治疗带来的治疗缺陷，且副作用极小。这些改变与高密度脂蛋白，过氧化物酶体增殖物激活的受体α和脂联素的大量减少以及肝脏和肌肉线粒体蛋白质的减少有关。瑞舒伐他汀对血脂异常的小鼠与骆驼WP联合治疗4周可改善这些参数。值得注意的是，骆驼可湿性粉剂和瑞舒伐他汀同时治疗的动物血脂异常的发生率显着降低。此外，骆驼可湿性粉剂成功克服了仅由瑞舒伐他汀治疗带来的治疗缺陷，且副作用极小。这些改变与高密度脂蛋白，过氧化物酶体增殖物激活的受体α和脂联素的大量减少以及肝脏和肌肉线粒体蛋白质的减少有关。瑞舒伐他汀对血脂异常的小鼠与骆驼WP联合治疗4周可改善这些参数。值得注意的是，骆驼可湿性粉剂和瑞舒伐他汀同时治疗的动物血脂异常的发生率显着降低。此外，骆驼可湿性粉剂成功克服了仅由瑞舒伐他汀治疗带来的治疗缺陷，且副作用极小。瑞舒伐他汀对血脂异常的小鼠与骆驼WP联合治疗4周可改善这些参数。值得注意的是，骆驼可湿性粉剂和瑞舒伐他汀同时治疗的动物血脂异常的发生率显着降低。此外，骆驼可湿性粉剂成功克服了仅由瑞舒伐他汀治疗带来的治疗缺陷，且副作用极小。瑞舒伐他汀对血脂异常的小鼠与骆驼WP联合治疗4周可改善这些参数。值得注意的是，骆驼可湿性粉剂和瑞舒伐他汀同时治疗的动物血脂异常的发生率显着降低。此外，骆驼可湿性粉剂成功克服了仅由瑞舒伐他汀治疗带来的治疗缺陷，且副作用极小。

更新日期：2018-01-02

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11